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A B S T R A C T
Protein aggregation, oxidative and nitrosative stress are etiological factors common to all major neurodegen-
erative disorders. Therefore, identifying proteins that function at the crossroads of these essential pathways may
provide novel targets for therapy. Oxidation resistance 1 (Oxr1) is a protein proven to be neuroprotective against
oxidative stress, although the molecular mechanisms involved remain unclear. Here, we demonstrate that Oxr1
interacts with the multifunctional protein, peroxiredoxin 2 (Prdx2), a potent antioxidant enzyme highly ex-
pressed in the brain that can also act as a molecular chaperone. Using a combination of in vitro assays and two
animal models, we discovered that expression levels of Oxr1 regulate the degree of oligomerization of Prdx2 and
also its post-translational modifications (PTMs), specifically suggesting that Oxr1 acts as a functional switch
between the antioxidant and chaperone functions of Prdx2. Furthermore, we showed in the Oxr1 knockout
mouse that Prdx2 is aberrantly modified by overoxidation and S-nitrosylation in the cerebellum at the pre-
symptomatic stage; this in-turn affected the oligomerization of Prdx2, potentially impeding its normal functions
and contributing to the specific cerebellar neurodegeneration in this mouse model.
1. Introduction
Neurodegenerative disorders are becoming more prevalent with
increased global life expectancy and a better understanding of the un-
derlying disease mechanisms will be essential for designing new ther-
apeutic approaches to tackle this growing health burden [1–3]. Aber-
rant proteostasis and increased oxidative and nitrosative (O/N) stress
have been strongly linked with the neurodegenerative process, irre-
spective of the etiology [4,5]. O/N stress arises from an excessive ac-
cumulation of reactive oxygen species (ROS) and reactive nitrogen
species (RNS) resulting from an imbalance between free radical pro-
duction and detoxification by antioxidant proteins [6]. Elevated levels
of O/N stress markers such as oxidised lipids and nitrated proteins have
been reported in post mortem tissue of individuals affected by major
neurodegenerative disorders such as Alzheimer's disease (AD), Parkin-
son's disease (PD), and amyotrophic lateral sclerosis (ALS) [7–9]. Im-
portantly, these markers are not only observed at the end-stage of the
disease but are also detected in peripheral blood of patients during the
course of the disease and pre-symptomatically in animal models of
these conditions [10–14]. For example, mouse models of ALS show
elevated levels of carbonylated proteins, a marker of ROS-induced
protein damage, before any motor neuron pathology or clinical features
are observed, suggesting that O/N stress is an early event of the neu-
rodegenerative process [15].
Protein aggregation is another important feature consistently ob-
served in neurodegenerative disease. Indeed, the formation of
https://doi.org/10.1016/j.freeradbiomed.2018.10.447
Received 24 July 2018; Received in revised form 28 October 2018; Accepted 29 October 2018
Abbreviations: Oxr1, Oxidation resistance 1; Prdx2, peroxiredoxin 2; PTMs, post-translational modifications; O/N, oxidative and nitrosative; ROS, reactive oxygen
species; RNS, reactive nitrogen species; AD, Alzheimer's disease; PD, Parkinson's disease; ALS, amyotrophic lateral sclerosis; PDI, protein disulfide-isomerase;
TBC1D24, TBC1 Domain Family Member 24; DOORS, deafness, onychodystrophy, osteodystrophy and mental retardation with seizures; Ncoa7, nuclear receptor
coactivator 7; HMW, high molecular weight; GPI/Gpi1, glucose-6-phosphate isomerase; Oxr1-FL, full-length Oxr1; CS, citrate synthase; SNOC, S-nitrosocysteine;
SNO-protein, S-nitrosylated protein; ORC, organomercury resin capture; BCA, bicinchoninic acid; IPTG, isopropyl β-D-1-thiogalactopyranoside; FOX, ferrous oxi-
dation-xylenol orange; veh, vehicle; DTT, dithiothreitol
⁎ Corresponding authors. Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford OX1 3PT, UK.
E-mail addresses: p.oliver@har.mrc.ac.uk (P.L. Oliver), mattea.finelli@ndcn.ox.ac.uk (M.J. Finelli).
Free Radical Biology and Medicine 130 (2019) 151–162
Available online 31 October 2018
0891-5849/ Crown Copyright © 2018 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
neurotoxic protein aggregates has been reported in brain and spinal
cord regions affected by AD, PD, and ALS [16]. In normal conditions,
chaperone proteins are employed to fold misfolded proteins and dis-
assemble protein aggregates, and thus play a key role in the global
cellular proteostasis [17]. In neurodegenerative disease, however, the
chaperone activity in cells is disrupted. For instance, mutations in the
gene encoding for the mitochondrial chaperone mtHsp70 have been
identified in patients with PD, and have been shown to disrupt mtHsp70
activity and to lead to apoptosis [18,19]. In addition, PTMs, such as S-
nitrosylation and sulfonylation, have been associated with dysregula-
tion of protein function. For instance, aberrant S-nitrosylation of the
chaperone protein disulfide-isomerase (PDI) inhibits its activity,
leading to neurodegeneration [20,21]. Therefore, identifying proteins
that function in both the O/N stress and proteostasis pathways may
produce valuable insights into the underlying pathogenic mechanisms
of neurodegenerative conditions.
Oxidation resistance 1 (OXR1) was originally identified as a gene
capable of rescuing bacterial oxidative DNA damage [22]. Subse-
quently, Oxr1 has been shown to act as a potent regulator of oxidative
stress in mammalian neurons that can also delay neurodegeneration in
vivo. Oxr1 possesses a highly conserved C-terminal TLDc domain shared
with four other proteins in mammals, several of which have been
proven to be important for brain function [23]. Mutations in the TLDc
domain of TBC1 domain family member 24 (TBC1D24) influence its
role in neuronal cell development and function and are associated with
a range of familial neurological disorders, including epilepsy and
deafness, onychodystrophy, osteodystrophy and mental retardation
with seizures (DOORS) syndrome [23–25]. Moreover, mice lacking all
Oxr1 isoforms present a progressive ataxic phenotype concomitant with
degeneration of granule neurons in the cerebellum from postnatal day
19 (P19) [26–28]. Conversely, over-expression of Oxr1 in vivo is able to
delay motor neuron degeneration and motor dysfunction in a mouse
model of ALS [29]. In vitro studies in mammalian cells also demon-
strated that levels of Oxr1 can modulate the sensitivity of neurons to
oxidative stress [26,28]: knock-down of Oxr1 leads to oxidative stress-
induced cell death while over-expression of Oxr1 reduces ROS levels
and apoptosis of cells subjected to oxidative stress [26,28]. Further-
more, studies in a range of experimental systems have demonstrated a
dysregulation of the expression of a number of antioxidant genes when
Oxr1 is disrupted. For example, glutathione peroxidase 2 (GPX2), heme
oxygenase-1 (HO-1), catalase (CAT) and peroxiredoxin 4 are reportedly
down-regulated in OXR1-depleted mammalian cell lines [30–32],
whereas in mosquitos, gene knock-down of OXR1 regulates the basal
levels of CAT and Gpx expression [33].
As well as Oxr1, the TLDc-containing protein nuclear receptor
coactivator 7 (Ncoa7) can reduce the levels of the O/N stress-induced
PTM, S-nitrosylation, in neurons [26]; thus taken together, these data
suggest that the TLDc proteins have the ability to reduce O/N stress.
However, no superoxide dismutase or catalase-like catalytic activity has
been detected for Oxr1, and the three-dimensional structure of the TLDc
domain provides no clues regarding the molecular function of this
important group of proteins [28,34,35]. In addition, Oxr1 has been
shown to reduce the aggregation and mislocalisation of the ALS-asso-
ciated proteins FUS and TDP-43 via protein interaction, although the
precise mechanism involved is currently unclear [36].
Here, we demonstrate that Oxr1 interacts with peroxiredoxin 2
(Prdx2), a highly abundant and potent antioxidant enzyme that also
possesses a chaperone function. Our results suggest that Oxr1 acts as a
functional switch for Prdx2 activity, from an H2O2 scavenger to a high
molecular weight (HMW) chaperone complex, through the modulation
of its overoxidation and S-nitrosylation. We also report an unexpected
and novel function for Oxr1 as a potential holdase.
2. Materials and methods
2.1. Reagents
Reagents used were as follows: Insulin (I0516, Sigma), citrate syn-
thase (C3260, Sigma), protease inhibitor (5871S, Cell Signaling), pro-
tease/phosphatase inhibitor (5872S, Cell Signaling), protease inhibitor
(11836170001, Roche). Antibodies used were: Prdx2 (10545–2-AP,
Proteintech), Prdx-SO2/3 (ab16830, Abcam), β-actin (ab8226, Abcam),
HA (H6908, Sigma), α-tubulin (Sigma), MYC (Sigma), Oxr1 [28].
2.2. Animals
Constitutive Oxr1 knockout (Oxr1d/d) mice maintained on a
C57BL6/J background have been previously described [27]. Oxr1 Tg
mice, where a full-length cDNA transgene of Oxr1-FL is expressed from
a ubiquitous actin-derived promoter, were also maintained on a
C57BL6/J background and have been previously described [28]. All
experiments were conducted in adherence with the guidelines set forth
by the UK Home Office regulations, and with the approval of the Uni-
versity of Oxford Ethical Review Panel.
2.3. Expression constructs
Mouse Prdx2 cDNA (NM_001317385.1) was cloned from total brain
cDNA extract into pET-22b vector with or without introducing
thrombin cleavage site (Thr) in frame with a His6 tag: F – 5′-GAGACA
TATGGCCTCCGGCAACGCGCAAATC-3′, R – 5′-GAGACTCGAGGCTGCC
ACGCGGCACCAGGTTGTGTTTGGAGAAGTATTCC-3′; or F – 5′-GAGAC
ATATGGCCTCCGGCAACGCGCAAATC-3′, R – 5′-GAGACTCGAGGTTGT
GTTTGGAGAAGTATTCC-3′, respectively. Mouse Oxr1-C (NM_
001130164) was cloned from total brain cDNA into pET-22b back-
bone in frame with His6 tag (F – 5′-GAGACATATGTCCCGTCTCTG
GTATGGGAAAAAAG-3′, R – 5′- GAGACTCGAGTTCAAAAGCCCAGATT
TCAATG-3′). For expression in mammalian cells, mouse Prdx2 was
cloned into pcDNA3.1 with a C-terminal MYC tag. All other constructs
used have been previously described [26,28].
2.4. Cell culture, transfection, and treatment
Neuro2a (N2a) and SH-SY5Y cells were cultured in DMEM with
GlutaMAX (Gibco) and Ham's F12:DMEM (Gibco) respectively, sup-
plemented with 10% fetal bovine serum (Gibco) and 1% penicillin-
streptomycin solution (Gibco) in an incubator at 37 °C in 5% CO2 at-
mosphere. Cells were seeded 24 h prior to transfection. Cells were
transfected using Fugene 6 (Promega) diluted in Opti-MEM (Gibco)
according to manufacturer's protocol. 24 h after transfection culture
media was changed to media supplemented with desired concentrations
of H2O2. For cell death assay, cells were treated with 500 μM H2O2 for
5 h, and for Prdx2 overoxidation experiments, cells were treated with
300 µM H2O2 for 1 h. Fluorescent microscope Axioplan2 Imaging (Carl
Zeiss) was used for cell death assay to visualise the pyknotic nuclei. For
S-nitrosocysteine (SNOC) treatment of SH-SY5Y cells, a fresh stock so-
lution of SNOC was prepared immediately before each use by mixing
200mM cysteine (Sigma) with 200mM NaNO2 (Sigma) supplemented
with HCl (0.5 N). Cells were treated with 200 μM SNOC for 30min.
Control cells were treated with a vehicle solution (HCl diluted in
water).
2.5. Immunoprecipitation and western blotting
SDS-PAGE- Tissue samples or cells were lysed in cold RIPA buffer
supplemented with protease inhibitor (Cell signaling) and 1% Triton X-
100 or 1% CHAPS in a tissue Precellys homogenizer (Bertin Corp.) (for
tissue) or by trituration with a syringe (for cells). Protein concentration
was assessed by bicinchoninic acid (BCA) assay (Novagen). For co-
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immunoprecipitation, protein extracts were incubated overnight at 4 °C
with either Prdx2 antibody, EZview MYC beads (Sigma) or G protein
sepharose beads (Sigma) only, as a control. Protein-antibody complexes
were pulled down using G protein sepharose beads (Sigma) and washed
with cold RIPA buffer. Immunoprecipitated proteins were incubated
with Laemmli loading buffer (Bio-Rad) or NuPAGE loading buffer (Life
Technologies) supplemented with 5% β-mercaptoethanol (Sigma) at
100 °C for 5min.
Blue Native-PAGE (BN-PAGE)- Brain and cerebella tissue samples
and cells were homogenised in cold PBS buffer supplemented with
protease/phosphatase inhibitors (New England Biolabs) using Precellys
homogenizer (only for tissue samples) and lysed by repeated freezing
and thawing (for tissue and cells). After measuring protein concentra-
tion using BCA assay (Novagen), samples were mixed with 5x loading
buffer (62.5mM Tris-HCl pH 6.8, 40% glycerol, 0.01% bromophenol
blue) and were resolved on 10% Bis-Tris native gel.
After samples were run on either SDS-PAGE or BN-PAGE, proteins
were transferred to PVDF membrane (Amersham). The membrane was
then blocked with 5% skim milk in PBST for 1 h at room temperature
and incubated overnight with primary antibodies at 4 °C. The mem-
branes were washed with PBST and incubated with secondary HRP-
conjugated antibodies and signal was detected using ECL or ECL Prime
Western Blotting detection kit (both Amersham) using an ImageQuant
LAS 4000 (GE Healthcare). Western blot signal was quantified using
ImageJ.
2.6. Protein expression and purification
Prdx2-His6 and Prdx2-Thr-His6 proteins were produced in E.coli
strain BL21(DE3) (Invitrogen) and purified according to protocol pub-
lished by Yan et al. [37]. Briefly, protein expression was induced at
OD600 ~0.7–0.8 by addition of isopropyl β-D-1-thiogalactopyranoside
(IPTG) (Sigma) to final concentration of 0.8 mM. After incubation on a
shaker for 5 h at 25 °C, bacterial cells were collected by centrifugation
and resuspended in 500mM NaCl PBS supplemented with protease
inhibitors. After sonication of the bacterial cultures and centrifugation
for 30min at 4 °C, recombinant His6-tagged protein was incubated with
1ml TALON metal affinity resin (Clontech) for 1 h at 4 °C. Proteins were
washed using increasing concentration of imidazole, and eluted with
500mM imidazole. Eluted samples were dialysed overnight against PBS
buffer at 4 °C using Slide-A-Lyzer dialysis cassette (Thermo Fisher). The
His6 tag was cleaved from Prdx2-Thr-His6 using the Thrombin Clean-
Cleave Kit (Sigma Aldrich) at 17 °C for 4 h, as per the manufacturer's
protocol and dialysed against PBS buffer following cleavage. Oxr1-C
was produced as described before [28]. Briefly, protein expression was
induced at OD600 ~ 0.8 by addition of IPTG to a final concentration of
0.8 mM. Bacterial cultures were incubated on a shaker for 16 h at 18 °C
and bacterial cells were collected by centrifugation. Protein was pur-
ified as described above. Full-length human OXR1 recombinant protein
expressed in E.Coli was purchased from Origene (TP760961). Purified
proteins were analysed by western blotting with anti-Prdx2 and anti-
Oxr1 antibodies. Protein concentrations were measured using Nano-
Drop spectrophotometer with extinction coefficients of 21,555M−1
cm−1 for Prdx2 and 38,055M−1 cm−1 for Oxr1-C and. DNA fragments
encoding TB1D24 full-length (aa 1–553) and TLDc domain (aa
336–553) were subcloned into the pFB-Lic-Bse for insect Sf9 cell ex-
pression and pNIC28-Bsa4 for E. coli expression, respectively. Re-
combinant full-length TBC1D24 was expressed in Sf9 cells, while the
TBC1D24 TLDc-domain was expressed in E.Coli and purified as above,
followed by size exclusion chromatography. The purity of the re-
combinant protein preparation was ascertained by coomassie staining
(Supplementary Fig. 1).
2.7. Peroxiredoxin activity assay
Prdx2 activity was assessed using ferrous oxidation-xylenol orange
(FOX) assay [38]. The assay solution contained 100 µM dithiothreitol
(DTT, Sigma Aldrich), 50 µM H2O2 (Sigma Aldrich), 2.2 µg recombinant
uncleaved purified Prdx2, with 0 or 0.95 µg Oxr1-C or 4.5 µg OXR1-FL.
The reaction was initiated by addition of H2O2 and quenched at ap-
propriate time points by addition of 200 μl of FOX reagent (1 part of
FOX A reagent (25mM ammonium ferrous sulfate (Sigma) in 2.5M
H2SO4 (Sigma)) and 100 parts of FOX B reagent (100mM sorbitol
(Sigma) with 125 µM xylenol orange (Sigma) in water)). Samples were
incubated at room temperature for at least 30min before reading ab-
sorbance at 560 nm with Fluostar Omega plate reader.
2.8. Chaperone activity assay
In vitro holdase activity of cleaved Prdx2 and Oxr1-C was assessed in
chemically- and thermally-induced aggregation assays. The ability of
Prdx2 and Oxr1-C to protect insulin from DTT-induced aggregation was
measured as change of absorbance at 650 nm at 25 °C. The reaction
solution contained 30 µg insulin (Sigma Aldrich) with or without 20 µg
Prdx2, with 22 µg (6 µM final concentration), 33 µg (9 µM) Oxr1-C,
22 µg Tbc1d24, 22 µg Tbc1d24 TLDc domain or 85 µg (6 µM) OXR1-FL
and was initiated by addition of DTT to a final concentration of
6.66mM. Ability of Prdx2 and Oxr1-C to protect citrate synthase (CS)
from aggregating was monitored by changes in absorbance at 360 nm
during incubation at 44 °C. Reaction solution contained 10 µg of CS and
10 µg of Prdx2, Oxr1-C or both in 50mM HEPES pH 8.0.
2.9. Biotin switch assay
The biotin switch assay was performed as previously described
using the reagents from the S-nitrosylated protein detection kit
(Cayman) [39]. For tissue, snap-frozen brains or cerebella were
homogenised in buffer A supplemented with protease inhibitors (Cell
Signaling) using a tissue Precellys homogenizer (Bertin Corp.). After
centrifugation at maximum speed for 30min at 4 °C, protein con-
centration was quantified using a BCA assay (Thermo Scientific) and an
equal amount of protein was used per sample. All subsequent steps were
performed protected from direct light and in amber tubes. Blocking
reagent provided in the kit was added, and samples were incubated for
30min at 50 °C with regular vortexing. Proteins were subsequently
precipitated using cold acetone to remove any trace of blocking re-
agent, and incubated at −20 °C for at least 30min, followed by cen-
trifugation at 3000g for 10min at 4 °C. Protein pellets were resuspended
in the labelling/reducing reagent provided and prepared as per the
manufacturer's instructions. A combined protein sample was incubated
with diluted dimethylformamide only as a negative control. Samples
were incubated for 1 h at room temperature on a shaker. Proteins were
acetone precipitated as above. Protein pellets were resuspended in wash
buffer provided; a fraction of the protein extracts was kept aside as
input to determine total Prdx2 levels. To pull down S-nitrosylated
proteins, protein extracts were incubated overnight at 4 °C on a shaker
with 50 μl EZview streptavidin beads (Sigma). Beads were washed three
times with wash buffer and resuspended in NuPAGE loading buffer
supplemented with β-mercaptoethanol, and boiled for 5min. Total
protein (input) and S-nitrosylated proteins were run on pre-cast Nu-
PAGE gels as per standard procedures. Results were expressed as in-
tensity of signal for SNO-Prdx2 over total level of Prdx2 per sample.
For cells, cells transfected for 48 h and treated with either vehicle or
SNOC were washed with PBS and scraped from the dish. After cen-
trifugation at 1000 rpm for 5min, cell pellets were resuspended directly
in blocking reagent diluted in buffer A and incubated at 50 °C for
30min. After centrifugation and subsequent acetone precipitation,
protein pellets were resuspended in labelling/reducing reagent and
incubated at room temperature for 1 h. After acetone precipitation,
proteins were resuspended in wash buffer and quantified by BCA assay
(Thermo Scientific). The subsequent steps are identical as for tissue
above.
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2.10. Organomercury resin capture (ORC)
ORC from brain and cerebellum tissue was performed as previously
described [40]. Briefly, samples were homogenised in homogenization
buffer (250mM HEPES free acid, 1 mM DTPA, 0.1 mM neocuproine, 1%
Triton X-100, pH 7.7) using a tissue Precellys homogenizer (Bertin
Corp.). Samples were clarified by centrifugation at full speed for 10min
at 4 °C and protein concentration was quantified by BCA assay (Thermo
Scientific). An equal amount of protein was used per sample. As a ne-
gative control a combined protein sample was incubated with the re-
ducing agent DTT (10mM) for 15min at room temperature. Proteins
were acetone precipitated and resuspended in blocking buffer (250mM
HEPES acid free, 1 mM DTPA, 0.1 mM neocuproine, 2.5% SDS, pH 7.7)
supplemented with 50mM blocking agent MMTS. Protein extracts were
incubated for 30min at 50 °C, with frequent vortexing, followed by
acetone precipitation. Protein pellets were resuspended in loading
Fig. 1. Oxr1 plays a role in the regulation of the oligomerization status of Prdx2 in vitro and in vivo. (A-B) Representative western blot of Prdx2 from protein extracts
of P18 wild-type control (Oxr1+/+) and Oxr1d/d brain tissue with the cerebellum removed (A) and the cerebellum alone (B). Quantification of the HMW Prdx2
complexes (###) and the Prdx2 dimer (#) is shown (N=8 animals per group (A) and N=3 (B)). (C) Western blot of Prdx2 from protein extracts of adult wild-type
and Oxr1 Tg mouse brains without the cerebellum. Quantification of the HMW Prdx2 complexes and the dimer is shown (N=3 animals per group). (D) Western blot
of Prdx2 from protein extracts of N2A cells transfected with either an empty vector or Oxr1-FL and treated with 300 µM H2O2 for 1 h. Quantification of the HMW
Prdx2 complexes, the Prdx2 dimer (#) and the decamer (##) is shown (N=3 independent repeats). For all panels, extracts were run on 10% BN-PAGE (native) gels
and levels of Prdx2 and β-actin (input) were determined for the same samples, but run in reducing conditions on separate gels. β-actin was used as a loading control.
Data are represented as mean ± SEM. Panels A-D: t-test; *p < 0.05, ***p < 0.001.
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buffer (250mM MES, 1mM DTPA, 1% SDS, pH 6.0) and ready to be
loaded on to the activated resin in glass columns; a fraction was kept
aside as input. Organomercury resin (produced by the laboratory of
Professor Harry Ischiropoulos University of Pennsylvania, USA and
provided by Dr Mark Crabtree, University of Oxford) was washed and
activated by consecutive washes with isopropanol, water, 0.1 M sodium
bicarbonate pH 8.8, and equilibration buffer (50mM NaCl, 50mM
MES, 1mM DTPA, pH 6.0). After the resin was drained, samples were
added and capped with 0.5ml loading buffer and incubated at room
temperature for 1 h protected from light to allow the reaction between
S-nitrosylated proteins and the organomercury resin. The S-nitrosylated
proteins cross-linked to the resin were then washed with consecutive 50
bed volumes of buffer A (50mM Tris-HCl, 0.3mM NaCl, 0.5% SDS, pH
7.5), buffer B (50mM Tris-HCl, 0.3mM NaCl, 0.05% SDS, pH 7.5),
buffer C (50mM Tris-HCl, 0.3 mM NaCl, 1% Triton X-100, 1M urea, pH
7.5), and buffer D (50mM Tris-HCl, 0.3 mM NaCl, 0.1% Triton X-100,
0.1 M urea, pH 7.5), followed by three washes of 200 bed volumes of
water. Bound S-nitrosylated protein were then eluted by incubating the
resin with 5% performic acid for 45min at room temperature. The
eluted proteins were precipitated by adding one volume of 100% TCA
to four volumes of protein sample and incubated overnight at 4 °C. After
centrifugation at full speed for 30min at 4 °C, protein pellets were
washed in cold acetone and resuspended in NuPAGE loading buffer
supplemented with β-mercaptoethanol, and boiled for 5min. Total
protein (input) and S-nitrosylated proteins were run on pre-cast Nu-
PAGE gels as per standard procedures. Results were expressed as in-
tensity of signal for SNO-Prdx2 over total level of Prdx2 per sample.
2.11. Statistical analyses
Statistical analysis was performed using Prism software using one-
way ANOVA or unpaired t-test. Data are presented as mean ± SEM.
3. Results
3.1. Oxr1 modulates the oligomerization state of the antioxidant enzyme
Prdx2
It has been shown recently that Oxr1 regulates the activity and
degree of oligomerization of the multifunctional enzyme glucose-6-
phosphate isomerase (GPI/Gpi1) via protein-protein interaction [27].
Therefore, seeing that Oxr1 can influence ROS levels as well as protein
multimer formation and aggregation, we tested the hypothesis that
Oxr1 is neuroprotective against O/N stress by regulating the function of
essential proteins within these two pathways [26,28,36,41]. As a pro-
mising candidate interactor for Oxr1, we selected peroxiredoxin 2
(Prdx2) because it acts both as a chaperone and an antioxidant as well
as being highly expressed in neurons [42–44]. Indeed, the expression
patterns of Prdx2 and Oxr1 overlap in the CNS, including the granule
cell layer of the cerebellum [26,42,45]. Furthermore, similar to the
knockout of Oxr1, loss of Prdx2 in mice leads to accumulation of ROS
and oxidative DNA damage, although this occurs in the CA1 region of
the hippocampus as opposed to the cerebellum of Oxr1 knockout mu-
tants [46].
Given that the multiple functions of Prdx2 are regulated by its de-
gree of oligomerization, we first tested whether Oxr1 levels would af-
fect Prdx2 oligomerization in the brain [47,48]. Using non-reducing
native PAGE to preserve protein complexes, we assessed Prdx2 oligo-
merization in tissues from a constitutive Oxr1 knockout mouse in which
all isoforms of the protein are disrupted (Oxr1d/d) [26–28]. Tissue
samples were collected at a pre-symptomatic timepoint (P18), prior to
the onset of neurodegeneration in this model. In wild-type (Oxr1+/+)
brain tissue, we observed a dimeric form of Prdx2 in addition to HMW
complexes with an apparent molecular weight of approximately
400 kDa, as previously described (Fig. 1A) [48–50]. Interestingly, there
was a significant decrease in these HMW Prdx2 complexes in the brain
of Oxr1d/d mice compared to wild-type controls, both in the brain
without the cerebellum (Fig. 1A) and in the cerebellum alone (Fig. 1B).
To confirm that Oxr1 levels regulate Prdx2 oligomerization, we next
assessed the levels of Prdx2 multimers in brains from adult mice
overexpressing an HA-tagged full-length Oxr1 (Oxr1-FL) cDNA trans-
gene (Oxr1 Tg) [28]. Conversely to the observations from Oxr1d/d
knockout mice, levels of the HMW Prdx2 complexes were significantly
increased in Oxr1 Tg tissue compared to wild-type controls (Fig. 1C).
Together, these data suggest that the levels of Oxr1 modulate Prdx2
oligomerization in vivo. To validate that higher levels of Oxr1 indeed
favour higher-order Prdx2 complexes, we next analysed the degree of
oligomerization of Prdx2 in cells over-expressing Oxr1 and upon
treatment with H2O2 to promote assembly of HMW Prdx2 complexes
via Prdx2 overoxidation [48,50,51]. Interestingly, in cells over-ex-
pressing Oxr1-FL, specific HMW Prdx2 complexes were detected -
namely its decameric species at the molecular weight of approximately
220 kDa - while this was not present in control vector-transfected cells
(Fig. 1D). Overall, our data suggest that Oxr1 is able to modulate Prdx2
oligomerization.
3.2. Oxr1 interacts with the antioxidant enzyme Prdx2
To understand the mechanism by which Oxr1 regulates the oligo-
merization of Prdx2, we next tested whether Oxr1 and Prdx2 could
interact. To assess binding between Prdx2 and Oxr1, we performed co-
immunoprecipitation experiments in neuronal N2A cells co-expressing
Prdx2 and either Oxr1-FL or the shortest Oxr1 isoform (Oxr1-C). The
latter isoform primarily consists of the TLDc domain, but is highly ex-
pressed in the brain and has a proven function as a neuroprotective
protein [26,28]. Both Oxr1 isoforms were found to co-im-
munoprecipitate with Prdx2 (Fig. 2A). The TLDc domain is common
between both Oxr1 isoforms, thus we went on to investigate whether
this interaction would be maintained with other TLDc-containing pro-
teins. We discovered that Prdx2 also interacts with full-length nuclear
receptor coactivator 7 (Ncoa7-FL), and to a lesser extent with the
shorter TLDc domain-containing isoform (Ncoa7-B) (Fig. 2A). We also
observed binding to Tbc1d24, suggesting that Prdx2 is a common
binding partner for most of the TLDc proteins (Fig. 2A). To investigate
whether the Oxr1 interaction occurs in vivo, we performed co-im-
munoprecipitation from wild-type mouse brain tissue and detected an
interaction between endogenous Oxr1 and Prdx2, confirming our in
vitro data (Fig. 2B).
3.3. Oxr1 and Prdx2 do not synergistically regulate H2O2–induced cell
death
To investigate the significance of the Oxr1:Prdx2 interaction, we
next tested systematically how Oxr1 and Prdx2 might influence each
other's functional roles. Both Oxr1 and Prdx2 have been shown to be
neuroprotective under oxidative stress; therefore, we quantified H2O2-
induced cell death in a neuronal cell line expressing either Oxr1, Prdx2
or both proteins [26,52]. Consistent with previous reports, over-ex-
pression of Oxr1-FL, Oxr1-C or Prdx2 significantly reduced cell death
under oxidative stress conditions; however, Prdx2 was significantly less
protective than Oxr1 in this assay (Fig. 2C) [26,28,53]. Co-expression of
Prdx2 together with Oxr1 did not alter significantly the neuroprotective
properties of Oxr1.
Considering that Prdx2 can reduce H2O2 at a high kinetic rate, we
next investigated whether the neuroprotection against oxidative stress
that is conferred by Oxr1 could be via regulation of Prdx2 activity
[54,55]. To test this, we carried out a peroxide activity assay that
measures reduction of H2O2 using purified recombinant proteins, and as
expected, recombinant Prdx2 was able to dramatically reduce H2O2
levels (Fig. 2D) [37]. Recombinant Oxr1-C and OXR1-FL were not,
however, able to reduce H2O2 levels in this assay, similar to what has
been observed previously (Fig. 2D) [28]. When Prdx2 and Oxr1-C were
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incubated together, no enhancement in the rate of H2O2 decay was
observed as compared to the rate observed for Prdx2 alone (Fig. 2D),
suggesting that Prdx2 and Oxr1 do not interact synergistically to reg-
ulate cell death under oxidative stress or to reduce H2O2 levels.
3.4. Oxr1 and Prdx2 both modulate protein aggregation in vitro
As well as being an antioxidant enzyme, Prdx2 also possesses hol-
dase activity [48,56]. Holdases are a class of chaperones that bind
unfolded or misfolded molecules and prevent them from aggregating in
an ATP-independent manner [17]. To investigate any functional inter-
actions between Oxr1 and Prdx2 that may modulate Prdx2 chaperone
activity, we used a well-established in vitro aggregation assay with re-
combinant proteins. Insulin was induced to form large aggregates by
incubation with DTT; its aggregation correlates with an increased tur-
bidity of the reaction solution, which can be quantified by spectro-
photometry [57]. Using this system, we observed a reduction in the
aggregation of insulin in the presence of recombinant Prdx2, as ex-
pected, while lysozyme, a non-chaperone control, did not affect ag-
gregation (Fig. 3A-C). Importantly, when Prdx2 was incubated with
recombinant Oxr1-C, this led to a further significant reduction in insulin
aggregation rate and in the aggregation at endpoint as compared to
Prdx2 alone; this suggests that Oxr1-C may enhance the chaperone
activity of Prdx2 (Fig. 3A-C). We confirmed these data by using a
Fig. 2. Prdx2 binds to TLDc proteins, but does not interact
functionally with Oxr1 to regulate H2O2-induced cell
death. (A) N2A cells were co-transfected with Prdx2-MYC
and HA-tagged TLDc constructs as indicated and data from
co-immunoprecipitations (IP) of the TLDc proteins using
an anti-MYC antibody are shown by immunoblotting for
HA (left panel). α-tubulin was used as a loading control for
the input samples (right panel). The asterisk (*) represents
non-specific IgG heavy chains. (B) Co-immunoprecipita-
tion of Oxr1-FL with Prdx2 from adult wild-type mouse
brain tissue (excluding the cerebellum). (C) N2A cells
transfected with the indicated constructs were treated
with 500 µM H2O2 for 5 h and cell death was quantified as
the number of pyknotic nuclei. 10 fields of view per con-
dition were quantified (N=100–150 cells per field of
view). (D) Changes in H2O2 concentration were monitored
using a colorimetric ferrous oxidation-xylenol orange
(FOX) assay over 25min with either recombinant purified
Prdx2, Oxr1-C, OXR1-FL or Prdx2 with Oxr1-C proteins
with 50 µM H2O2. (N= 3 independent repeats). Data are
represented as mean ± SEM. Panel C: 1-way ANOVA;
***p < 0.001 compared to empty vectors, ###p < 0.001
compared to transfection with Prdx2.
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second aggregation assay that utilises thermally-induced aggregation of
citrate synthase (CS). In agreement with the insulin aggregation data,
the presence of Prdx2 reduced the thermally-induced aggregation of CS,
and the rate of aggregation was significantly reduced further when
Prdx2 was co-incubated with Oxr1-C (Fig. 3D-F).
Surprisingly, when these assays were performed with Oxr1-C only,
we detected a significant reduction of approximately 50% in both the
chemically- and thermally-induced aggregation rate of insulin and CS
(Fig. 3D-I). Given that these assays are cell-free, these data are not re-
liant on other proteins, thus suggesting that Oxr1-C possesses a poten-
tial holdase activity. To confirm this observation, we tested whether
increasing Oxr1-C concentration would lead to an increase in protective
activity against chemically-induced protein aggregation. We did ob-
serve a significant decrease in substrate aggregation rate as well as a
slight reduction in the aggregation at end point with an increased
concentration of Oxr1-C, further supporting a chaperone activity for
Oxr1-C (Fig. 3G-I).
As the Oxr1-C isoform is mainly comprised of the TLDc domain, our
data indicate that the chaperone activity we observe may be conserved
in other TLDc-containing proteins. To test this hypothesis, we quanti-
fied the chaperone activity of full-length OXR1 (OXR-FL) and TBC1D24
using the chemically-induced protein aggregation assay. Using a re-
combinant OXR1-FL, we detected a significant reduction in both the
aggregation rate and aggregation at end point compared to the control,
suggesting that OXR1-FL also possesses holdase activity (Fig. 3G-I).
Interestingly, we did not detect any reduction in the formation of in-
sulin aggregates when incubated with full-length TBC1D24, suggesting
that TBC1D24 does not possess holdase activity (Fig. 3G-I). We per-
formed a similar experiment using a recombinant protein constituted of
only the C-terminal TLDc domain of TBC1D24. Similar to full-length
TBC1D24, the TLDc domain alone did not show any chaperone activity
(Fig. 3G-I). Therefore, we have identified a novel activity for Oxr1 as a
Fig. 3. Prdx2 and Oxr1 possess holdase activity. (A-C) DTT-induced insulin aggregation assay using recombinant Prdx2 and Oxr1-C with lysozyme as a negative
control. Absorbance readings at 650 nm were taken every 3min (A). Quantification of the aggregation rate (B) and absorbance at endpoint (C) are shown. (D-F)
Thermally-induced citrate synthase (CS) aggregation assay using recombinant Prdx2 and Oxr1-C. Absorbance readings at 360 nm were taken every 3min (D).
Aggregation rate (E) and absorbance at end point (F) are shown. (G-I) DTT-induced insulin aggregation assay using two concentrations (6 µM and 9 µM) of re-
combinant Oxr1-C or human OXR1-FL (6 µM), in parallel with human TBC1D24 and the TLDc domain of TBC1D24 (TBC1D24 TLDc). Absorbance readings at 650 nm
were taken every 3min (G). Quantification of the aggregation rate (H) and absorbance at endpoint (I) are presented. (A-I) All values are shown as normalized to the
background signal. Data are represented as mean ± SEM. B, C, H, I, E, F: t-test, *p < 0.05, **p < 0.01, ***p < 0.001 as compared to insulin (B, C, H, I) or CS (E,
F), ##p < 0.01, ###p < 0.001 as compared to insulin + Prdx2 (B, C, H, I) or CS + Prdx2 (E, F), §§§p < 0.001 as compared to insulin + Oxr1-C 6 μM (H, I).
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potential holdase that is likely not conserved with the related TLDc
protein TBC1D24.
3.5. Oxr1 modulates Prdx2 post-translational modifications (PTMs)
Prdx2 function is regulated by its level of oligomerization and
through PTMs such as overoxidation and S-nitrosylation, in addition to
conformational changes [48,58–60]. In particular, reversible oxidation
of catalytic cysteine residues occurs during the catalytic cycle of Prdx2:
in the presence of low levels of H2O2, Prdx2 is oxidised and reactivated,
while under high levels of H2O2, its cysteine residues are overoxidized,
forming sulfinic and sulfonic acid (Prdx-SO2/3), which inactivates its
antioxidant activity but stabilizes the HMW complexes which drive its
chaperone activity [48,51,61]. Given our findings that Oxr1 levels
modulate Prdx2 oligomerization, we next investigated whether Oxr1
could affect Prdx2 overoxidation. We first assessed overoxidation of
endogenous Prdx2 in vitro by quantifying the levels of Prdx2-SO2/3 over
the total level of Prdx2 from H2O2-treated cells. Using an antibody that
recognises overoxidized Prdx1, Prdx2, Prdx3 and Prdx4, we confirmed
previously reported overoxidation of the aforementioned Prdxs induced
by H2O2 treatment [62]. Interestingly, under these conditions, levels of
Prdx2 overoxidation were significantly higher in cells overexpressing
Oxr1-FL (Fig. 4A) and a similar effect was observed in cells over-
expressing Oxr1-C (Fig. 4B). This suggests that Oxr1 modulates, directly
or indirectly, Prdx2 overoxidation. We next tested if levels of Oxr1
would similarly affect overoxidation of Prdx2 in vivo by using the cer-
ebellum and the remaining brain tissue from Oxr1 Tg mice or control
littermates. Similar to what we observed in vitro in Oxr1 over-expres-
sing cells, a significant increase in Prdx2 overoxidation levels in brain of
transgenic animals were detectable as compared to wild-type mice
(Fig. 4C). There was also a significant increase in Prdx2-SO2/3 levels in
cerebellar tissue from Oxr1 Tg mice (Fig. 4D). To further investigate the
role of Oxr1 in regulating Prdx2 overoxidation, we analysed the levels
of Prdx-SO2/3 in brains from Oxr1d/d mice as compared to controls at
the presymptomatic P18 timepoint. We did not observe any significant
changes in Prdx2 overoxidation in the brain (Fig. 4E); however, levels
of Prdx2-SO2/3 were significantly reduced in cerebella from Oxr1d/d
animals as compared to controls (Fig. 4F). These data suggest that Oxr1
regulates levels of Prdx2 overoxidation; interestingly, this occurs dif-
ferentially in the cerebellum – the site of neurodegeneration in the
Oxr1d/d mutant – as compared to the rest of the brain.
S-nitrosylation is another essential PTM regulating Prdx2 function.
Indeed, addition of an NO group at its cysteine residues has been shown
to reduce the antioxidant activity of Prdx2 [58]. To test whether Oxr1
would have an effect on Prdx2 S-nitrosylation in vitro, we used a neu-
ronal cell line SH-SY5Y treated with the physiological cell-permeable
NO-donor, S-nitrosocysteine (SNOC), to induce S-nitrosylation of pro-
teins. Using a biotin switch assay, we quantified levels of S-nitrosylated
endogenous PRDX2 (SNO-PRDX2) and found that cells treated with
SNOC show a significant increase in levels of SNO-PRDX2, as previously
described (Fig. 5A) [58]. However, both in vehicle- and SNOC-treated
conditions, the levels of SNO-PRDX2 were significantly reduced when
cells were over-expressing Oxr1-FL or Oxr1-C as compared to control
cells suggesting that Oxr1 reduces SNO-Prdx2 levels (Fig. 5A). To test
whether similar observations could be made in vivo, we quantified the
levels of SNO-Prdx2 in brain and cerebellum extracts from Oxr1 Tg
mice and wild-type controls. While levels of SNO-Prdx2 in the brain
were slightly decreased without reaching significance (Fig. 5B), we
showed a significant reduction in the levels of SNO-Prdx2 in the cere-
bella of Oxr1 Tg mice as compared to controls (Fig. 5C). To investigate
further whether levels of Oxr1 modulate SNO-Prdx2, we next quantified
the levels of SNO-Prdx2 in Oxr1d/d mice using two different approaches:
first, the originally described biotin switch method to detect SNO-pro-
teins, that converts S-nitrosylated residues to biotinylated cysteines
which are then immunoprecipitated by streptavidin beads, and second,
a newly developed approach, organomercury resin capture (ORC) that
relies on the selective and semi-stable reaction of S-nitrosylated re-
sidues with phenylmercury compounds of an organomercury resin
[40,63]. We showed that SNO-Prdx2 levels were similar in the brain of
Oxr1d/d and control animals, using either the biotin switch or ORC
approach (Fig. 5D and 5F). In contrast, a significant increase in the
levels of SNO-Prdx2 was seen with both approaches in cerebella of
Oxr1d/d mice as compared to controls (Fig. 5E and 5G) suggesting that
Oxr1 participates in the modulation of Prdx2 S-nitrosylation in the
cerebellum. Together, we have shown that Oxr1 modulates two essen-
tial Prdx2 PTMs, overoxidation and S-nitrosylation.
4. Discussion
Our current study sheds new light on the molecular mode of action
of Oxr1 as a functional switch for the essential antioxidant and cha-
perone Prdx2. Indeed, we show that Oxr1 modulates oligomerization of
HMW Prdx2 chaperone complexes and key PTMs regulating the dual
functions of Prdx2.
Our study is in accordance with our previous observations that Oxr1
reduces aggregation of the mutated ALS-associated TDP-43 and FUS
proteins in cellular models of ALS; this process relies on the interaction
between Oxr1 and TDP-43 or FUS, but is independent of the proteasome
or autophagy [36]. Based on our current findings, we hypothesise that
Oxr1 may reduce protein aggregation first through its chaperone ac-
tivity and second by favoring the formation of HMW Prdx2 chaperone
complexes. Another key function described for Oxr1 is its ability to
reduce levels of ROS and oxidative stress markers in oxidative stress-
treated neurons as well as in SOD1G93A ALS mouse model [26,29].
However, Oxr1 has no direct catalytic activity, thus it has remained
unclear how Oxr1 could carry out this role. Here, we showed that Oxr1
regulates the activity of the antioxidant protein Prdx2, in particular, by
modulating two key PTMs of Prdx2, its overoxidation and S-nitrosyla-
tion: loss of Oxr1 increases SNO-Prdx2 and reduces its overoxidation,
while increasing Oxr1 levels leads to the opposite effect. This is sig-
nificant because these PTMs regulate Prdx2 antioxidant activity and are
intertwined: S-nitrosylation of Prdx2 reduces its H2O2-induced over-
oxidation and inhibits its antioxidant activity [58]. By affecting both
the degree of oligomerization and the PTMs of Prdx2, Oxr1 could po-
tentially fine-tune the amount of peroxidases versus chaperones in cells.
A slight shift in this proportion could have a major impact on the global
cell function given that Prdxs represent 0.2–0.8% of the total soluble
protein fraction in cells and tissues, and that Prdx2 is highly expressed
in neurons [42–44,64]. Therefore, Oxr1 may indirectly regulate the
levels of oxidative stress in cells by modulating the PTMs of Prdx2 and
subsequently fine-tuning its antioxidant activity. This newly described
function is likely to run in concert with the proposed role for Oxr1 as a
regulator of antioxidant gene expression, this latter regulatory hy-
pothesis being supported by a number of studies that have combined
OXR1 knock-down with genome-wide or targeted transcriptomics
[30,33]. Further work is required to understand the molecular me-
chanisms involved, although there is evidence that gene modulation via
p53-associated pathways is more plausible than Oxr1 acting upstream
of the antioxidant Nrf2 signaling cascade [30,31].
The current study also provides an insight into the link between loss
of Oxr1 and cellular degeneration in the cerebellum of the Oxr1d/d
mouse [28]. We observed higher levels of SNO-Prdx2 and reduced le-
vels of Prdx2-SO2/3 in the neurodegenerative Oxr1 knockout mouse at a
presymptomatic stage, specifically in the cerebellum - the only brain
region affected in this mutant - suggesting that aberrant PTM of Prdx2
may participate in the neurodegeneration observed in this mouse. Im-
portantly, SNO-Prdx2 breaks the normal redox cycle that regenerates
Prdx2, inhibiting Prdx2 antioxidant activity and leading to high levels
of oxidative stress in cells [58]. Increased levels of SNO-Prdx2 have
been observed in the brain of the PQ/MB-exposed PD mouse model, as
well as in dopaminergic neurons differentiated from induced plur-
ipotent stem cells from PD patients and in post mortem brains of PD
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patients, suggesting that SNO-Prdx2 participates in the neurodegen-
erative process [58,65]. It was also shown in vitro that S-nitrosylation of
Prdx2 led to a reduction of Prdx2-SO2/3 and of its neuroprotective
function against H2O2 –induced apoptosis [58]. Therefore, our current
model is that loss of Oxr1 in the knockout mouse model impairs Prdx2
chaperone activity through reduction of HMW Prdx2 chaperone com-
plexes and reduction of the complexes-stabilising PTM, Prdx2-SO2/3. In
addition, Prdx2 antioxidant activity is also inactivated by the increase
in S-nitrosylation of Prdx2. These changes in PTMs being cerebellum-
specific, this may lead to a detrimental increase in protein aggregation
and oxidative stress in the cerebellum, precipitating the degeneration of
the cerebellar granule cells in Oxr1 knockout animals. Of note, we fo-
cused here on overoxidation and S-nitrosylation of Prdx2; however,
Prdx2 function can be affected by other PTMs, such as phosphorylation
and nitration, which have also been involved in neurodegeneration
[66].
Using two in vitro assay systems, we have discovered that Oxr1-C
and OXR1-FL possess a potential holdase activity. Because Oxr1-C is
almost exclusively constituted of the TLDc domain, we tested whether
this function was shared with another TLDc-containing protein.
Surprisingly, however, TBC1D24 did not possess any holdase activity;
neither the full-length protein nor the TLDc domain alone. This inter-
esting finding indicates that, although all TLDc-containing proteins are
neuroprotective, they may also carry out their own specific functions
[23]. This may be driven in part by key residues in the TLDc domain
that are yet to be identified. Importantly, we also showed that Tbc1d24
interacts with Prdx2, suggesting that the holdase activity is independent
of the ability to bind Prdx2. Here, we have focused on the interplay
between Oxr1 and Prdx2; yet the fact that Prdx2 has the ability to bind
to other TLDc-containing proteins suggests that functional compensa-
tion and competition with other TLDc proteins may play a part, and
would require further investigation.
5. Conclusions
In summary, our study not only discovered a new function for Oxr1
as a potential holdase, it also identified a novel mode of action for Oxr1,
acting on the oxidative stress response and protein aggregation by
modulating the oligomerization and PTMs of the fundamental anti-
oxidant enzyme Prdx2. Our study also places Oxr1 at the intersection
Fig. 4. Oxr1 modulates overoxidation of Prdx2 catalytic residues in vitro and in vivo. (A-B) N2A cells were transfected with either Oxr1-FL (A) or Oxr1-C (B) and
treated with 300 µM H2O2 for 1 h. Representative image of western blots and quantification of Prdx2 overoxidation is shown as the ratio of Prdx2-SO2/3 to total Prdx2
(N=6 independent repeats for Oxr1-FL and N=3 independent repeats for Oxr1-C). (C-F) Representative westerns blots of protein extracts from an adult Oxr1
overexpressing mouse (Oxr1 Tg) (C-D) and a P18 Oxr1 knockout (Oxr1d/d) mouse (E-F) from both the brain lacking the cerebellum and cerebellar tissues, with
quantification of Prdx2 overoxidation compared to wild-type controls (N=3–4 animals per group). β-actin was used as a loading control. Data presented as
mean ± SEM. Panels A-F: t-test; *p < 0.05.
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between two key pathways involved in the neurodegenerative process.
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